HATS trial

Study / Research

A small angiographic trial (around 100 subjects) that studied niacin and indicated improved lumen of arteries in people with CAD, but its claims of 90% event reduction were considered disingenuous due to lack of placebo and small sample size.

Mentioned in 1 video

Videos Mentioning HATS trial

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

Peter Attia MD

A small angiographic trial (around 100 subjects) that studied niacin and indicated improved lumen of arteries in people with CAD, but its claims of 90% event reduction were considered disingenuous due to lack of placebo and small sample size.